miR-218 suppresses the proliferation of osteosarcoma through downregulation of E2F2.
E2F2
children
microRNA-218
microRNAs
osteosarcoma
proliferation
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
05
08
2016
accepted:
04
09
2018
entrez:
19
1
2019
pubmed:
19
1
2019
medline:
19
1
2019
Statut:
ppublish
Résumé
Osteosarcoma is the most common primary malignant bone tumor type in children and adolescents under 20 years of age. Biological characteristics include invasiveness, metastasis, abnormal differentiation and loss of contact inhibition. microRNAs (miRNAs) are involved in the transcriptional and post-transcriptional regulation of target mRNAs. Previous studies have demonstrated that miR-218 inhibits tumor formation and progression in glioma, colon cancer and renal cell carcinoma; however, the mechanism of action of miR-218 in osteosarcoma has not been completely determined. In the present study, it was demonstrated that miR-218 exhibited low expression and targeted E2F2 in osteosarcoma cells. Additionally, overexpression of miR-218 inhibited osteosarcoma cell proliferation, with the opposite result occurring following the knockdown of miR-218. Furthermore, it was determined that miR-218 inhibited tumor formation and reduced the expression of E2F2 and proliferating cell nuclear antigen in nude mice. Collectively, the present data demonstrated that miR-218 serves an important role in suppressing the proliferation of osteosarcoma cells, potentially regulated by E2F2, which may provide a novel protein marker for the treatment of osteosarcoma.
Identifiants
pubmed: 30655803
doi: 10.3892/ol.2018.9576
pii: OL-0-0-9576
pmc: PMC6313196
doi:
Types de publication
Journal Article
Langues
eng
Pagination
571-577Références
Genes Dev. 2001 Feb 1;15(3):267-85
pubmed: 11159908
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Oncol Rep. 2006 Mar;15(3):693-700
pubmed: 16465432
Rev Recent Clin Trials. 2008 Sep;3(3):228-31
pubmed: 18782081
Cell Cycle. 2008 Dec 15;7(24):3915-27
pubmed: 19066456
Mol Carcinog. 2010 Feb;49(2):152-6
pubmed: 19798698
Nat Rev Cancer. 2009 Nov;9(11):785-97
pubmed: 19851314
Cancer Treat Res. 2009;152:447-57
pubmed: 20213407
Cell. 2012 Apr 27;149(3):515-24
pubmed: 22541426
Oncol Rep. 2012 Sep;28(3):1013-21
pubmed: 22766851
Oncol Lett. 2010 Nov;1(6):935-940
pubmed: 22870090
Plant Cell. 2013 Jul;25(7):2383-99
pubmed: 23881412
Asian Pac J Cancer Prev. 2013;14(6):3681-4
pubmed: 23886165
Mol Med Rep. 2013 Oct;8(4):1111-7
pubmed: 23970061
Cell Death Dis. 2013 Oct 24;4:e874
pubmed: 24157868
Tumour Biol. 2014 May;35(5):4209-17
pubmed: 24375253
Trends Mol Med. 2014 Aug;20(8):460-9
pubmed: 25027972
Biotechnol Lett. 2015 Mar;37(3):523-32
pubmed: 25362258
Tumour Biol. 2015 Mar;36(3):1511-8
pubmed: 25374061
Asian Pac J Trop Med. 2014 Dec;7(12):1000-4
pubmed: 25479631
Biochem Biophys Res Commun. 2015 Jan 16;456(3):804-9
pubmed: 25511701
Int J Oncol. 2015 Apr;46(4):1543-50
pubmed: 25647078
Mol Med Rep. 2015 Jul;12(1):1016-22
pubmed: 25816091
Tumour Biol. 2015 Sep;36(10):8015-23
pubmed: 25967457
Int J Mol Med. 2015 Jul;36(1):93-102
pubmed: 25999024
Cell Mol Neurobiol. 2015 Nov;35(8):1165-73
pubmed: 26012781
Oncol Lett. 2015 Jun;9(6):2743-2749
pubmed: 26137139
Chin J Cancer Res. 2015 Jun;27(3):247-57
pubmed: 26157321
Tumour Biol. 2016 Mar;37(3):2891-900
pubmed: 26409449
Oncotarget. 2016 Apr 12;7(15):20324-37
pubmed: 26967247
Mol Cell Biol. 1996 Mar;16(3):1047-57
pubmed: 8622649